| Additive effects of amrubicin with cisplatin on human lung cancer cell lines. | |
| | |
MedLine Citation:
|
PMID: 12375699 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Amrubicin (AMR) is a novel, completely synthetic 9-aminoanthracycline derivative. Amrubicinol, the C-13 alcohol metabolite of AMR, inhibits purified human topoisomerase II (topo II). We examined the effect of the combination of cisplatin (CDDP) and amrubicinol in vitro using a small cell lung cancer cell line (SBC-3) and an adenocarcinoma cell line (Ma-1), by WST-1 assay and isobologram analysis. When the two drugs were used together either simultaneously or sequentially, their combined effects were additive. A high concentration of CDDP (300 microM) enhanced the topo II inhibitory activity of amrubicinol as determined by kinetoplast-DNA decatenation assay. On the other hand, amrubicinol increased formation of DNA interstrand cross-links (ICL) in the cells, as determined using ethidium bromide fluorescence binding assay (EBFA), for simultaneous exposure to CDDP (0-300 microM) and amrubicinol (2 microM) compared with CDDP alone. These biological interactions might result in additive interaction between amrubicinol and CDDP. |
| | |
Authors:
|
Setsuko Yamauchi; Shinzoh Kudoh; Tatsuo Kimura; Kazuto Hirata; Junichi Yoshikawa |
Related Documents
:
|
10626359 - The role of dna mismatch repair in cisplatin mutagenicity. 6890669 - Structures of the adducts formed between [pt(dien)cl]cl and dna in vitro. 3822839 - Characterization of the ternary complexes formed in the reaction of cis-diamminedichlor... 22771949 - Efficient reconstitution of transcription elongation complexes for single-molecule stud... 6682809 - Liquid crystalline microphases of dna molecules complexed with compounds of platinum(ii). 20023919 - The role of bridging ligands in determining dna-binding ability and cross-linking patte... 16838839 - Segregation of partly melted dna molecules. 566079 - Systematics of hanseniaspora zikes and kloeckera janke. 3549359 - Dam methylase from e. coli. circular dichroism investigations of the secondary structur... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Osaka city medical journal Volume: 48 ISSN: 0030-6096 ISO Abbreviation: Osaka City Med J Publication Date: 2002 Jun |
Date Detail:
|
Created Date: 2002-10-11 Completed Date: 2002-11-04 Revised Date: 2006-11-20 |
Medline Journal Info:
|
Nlm Unique ID: 0376413 Medline TA: Osaka City Med J Country: Japan |
Other Details:
|
Languages: eng Pagination: 69-76 Citation Subset: IM |
Affiliation:
|
The First Department of Internal Medicine, Osaka City University Medical School, Osaka, Japan. m6640897@msic.med.osaka-cu.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anthracyclines* Antibiotics, Antineoplastic / pharmacology* Antineoplastic Agents / pharmacology* Cisplatin / pharmacology* DNA / metabolism DNA Topoisomerases, Type II / antagonists & inhibitors* Drug Synergism Enzyme Inhibitors / pharmacology* Humans Lung Neoplasms / drug therapy*, pathology Tumor Cells, Cultured |
| Chemical | |
Reg. No./Substance:
|
0/Anthracyclines; 0/Antibiotics, Antineoplastic; 0/Antineoplastic Agents; 0/Enzyme Inhibitors; 0/amrubicin; 15663-27-1/Cisplatin; 9007-49-2/DNA; EC 5.99.1.3/DNA Topoisomerases, Type II |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Brachytherapy for the prevention of neointimal hyperplasia in the canine inferior vena cava after st...
Next Document: Chest wall resection in general thoracic surgery.